Clinical Report: ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Overview

The ASCENT-03 study demonstrated that sacituzumab govitecan significantly improves progression-free survival in patients with advanced triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors.

Background

Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer with limited treatment options, particularly for patients ineligible for immune checkpoint inhibitors. The introduction of novel therapies like sacituzumab govitecan may provide new avenues for improving patient outcomes in this population.

Data Highlights

Key Findings

• Sacituzumab govitecan improved median progression-free survival (PFS) to 9.7 months compared to 6.9 months with standard chemotherapy (HR 0.62; p<0.0001).
• Confirmed overall response rate (ORR) was 50% for sacituzumab govitecan versus 47% for chemotherapy.
• The study enrolled 558 previously untreated patients with locally advanced unresectable or metastatic TNBC.
• Overall survival data were immature at the time of the study's approval.
• Biomarker subgroup analyses indicated efficacy across predefined subgroups.

Clinical Implications

The findings from ASCENT-03 suggest that sacituzumab govitecan may be a viable first-line treatment option for patients with advanced TNBC who are not candidates for PD-1/PD-L1 inhibitors. Clinicians should consider this therapy in the context of individual patient eligibility and treatment goals.

Conclusion

The ASCENT-03 study provides evidence for the use of sacituzumab govitecan in advanced TNBC.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
2. NCCN Guidelines, CancerNetwork, 2026 -- NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
3. Sara Tolaney, MD, MPH, ASCENT-03 Study Presented by Sara Tolaney, MD, MPH, Dana-Farber, 2026 -- ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
4. dana-farber — ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
5. dana-farber — ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
6. dana-farber — SABCS 2022: Sara Tolaney, MD, MPH
7. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer | FDA
8. NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium | CancerNetwork
9. ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i). | Journal of Clinical Oncology
10. Sacituzumab Govitecan With Pembrolizumab Extends Progression-Free Survival 2 for Some People With Metastatic Triple-Negative Breast Cancer - ASCO